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Abstract 19 
Iodine-insufficiency is now a sustained issue in the UK and other European countries, due to 20 
low intakes of dairy and seafoods (especially where iodine fortification is not in place). Here, 21 
we tested commercially-available encapsulated edible seaweed (Napiers Hebridean 22 
Seagreens® Ascophyllum nodosum species - NaHS) for its acceptability to consumers, iodine 23 
bioavailability and the impact of a 2-week long daily supplementation on iodine levels and 24 
thyroid function. Healthy non-pregnant women of childbearing age, self-reporting low dairy 25 
and seafood consumptions, with no history of thyroid or gastro-intestinal disease were 26 
recruited. Seaweed iodine (712 µg, in 1g seaweed) was modestly bioavailable at 33% (IQR 27 
28-46) of the ingested iodine dose, compared to 59% (IQR 46-74) for potassium iodide 28 
(n=22). After supplementation (2 weeks, 0.5g seaweed daily, n=42), urinary iodine excretion 29 
increased from 78 µg/L (IQR 39-114) to 140 µg/L (IQR 103-195), p<0.001. Thyroid 30 
stimulating hormone increased from 1.5 mUI/L (IQR 1.2-2.2) to 2.1 mUI/L (IQR 1.3-2.9) 31 
(p<0.001) with two subjects exceeding the normal range after supplementation (but normal 32 
free thyroxine). There was no change in other thyroid hormones levels after supplementation. 33 
The seaweed was palatable and acceptable to consumers as a whole food or as an ingredient, 34 
and effective as a source of iodine in an insufficient population. Incorporation in staple foods 35 
would provide an alternative to fortification of salt or other foods with potassium iodine. 36 
 37 
Keywords: Iodine, women, seaweed, Ascophyllum nodosum, bioavailability, thyroid 38 
function, childbearing age 39 
 40 
  41 
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Introduction 42 
Iodine is essential for the synthesis of the thyroid hormones triiodothyronine (T3) and 43 
thyroxine (T4) which play a key roles in metabolism, and are vital for a growing fetus, for 44 
normal growth and brain development 1. While hypothyroidism complicates some 45 
pregnancies 2, it does not preclude hypothyroid women to become pregnant 3, and iodine 46 
intake is crucial during the period surrounding child-bearing.  When the iodine intake is 47 
below the recommended intake (250 µg/day in pregnancy 4 although a new threshold value of 48 
200 µg/day has been proposed 5), adequate secretion of the thyroid hormones may still be 49 
achieved by physiological adaptation. Modifications of thyroid and pituitary  activities 50 
increases thyroid stimulating hormone (TSH) secretion, which enhances production of T3 51 
relative to T4 and rapid iodine turnover 
6, but fetal supply and placental transfer remain low.  52 
For epidemiological purposes, iodine insufficiency is defined as a population, or subgroup, 53 
with a median urinary excretion (UIC) less than 100 µg/l for non-pregnant adults, and below 54 
150 µg/L for groups of pregnant women4. While iodine fortification of common foods is 55 
widespread, it is not provided in all countries.  There is no requirement for iodine fortification 56 
of foods in UK, and iodine fortification is unusual. There is growing concern that subclinical 57 
iodine deficiency may be emerging in post-industrial countries previously assumed to be 58 
iodine sufficient and there is currently very little evidence about the need for specific dietary 59 
advice, or for iodine fortification / supplementation targeted towards these two key 60 
vulnerable groups: young women and their infants. 61 
With dairy and seafoods as main dietary source of iodine 7, the UK has been considered 62 
iodine replete. Areas with historical endemic goitre (‘Derbyshire neck’) no longer see clinical 63 
dietary hypothyroidism, in what was hailed an accidental public health success, following 64 
change to farming practice and supplementation of dairy herds 8.  However, a recent survey of 65 
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British schoolgirls has highlighted mild iodine deficiency with median urinary iodine 66 
concentrations of 80 µg/L 9. Similar results were found in a Scottish survey of women of 67 
childbearing age 10. Although few people have frank iodine deficiency and hypothyroidism, a 68 
low or marginal intake presents a potential hazard in pregnancy due to the increased demand 69 
placed on maternal thyroid function 11. This level of iodine insufficiency in the population is 70 
sufficient to impair intellectual development of future generations. Bath et al. showed that 71 
low maternal iodine status in pregnancy (individual iodine-to-creatinine ratios below 150 µg/g 72 
in spot samples) was associated with decreased cognitive functions in the ALSPAC cohort of 73 
1040 children from the south of England 12. While there is no lack of availability of dietary 74 
iodine in these regions 13, the explanation may be that many of the young female population 75 
commonly exclude fish and/or dairy products from their diets, for social or other reasons, 76 
leading to either low or marginal iodine intakes 14. 77 
Seaweeds used to feature as cheap and natural traditional foods in the British diet 15 until 78 
recently. European standards have later come in to ensure suitability as a human food. 79 
Despite this, it is still rather neglected throughout Europe, with little data available on the 80 
range of seaweed products for sale in the UK or Europe (Norman et al. in 1988 studied 81 
mainly a range of kelp tablet, citing laverbread and Nori seaweed sheet as other seaweed 82 
products available 16. Data on its consumption are lacking, despite the fact that it is a rich 83 
source of iodine, with wide variation between species (from 16 to 8165 µg/g) 17.  84 
This study aimed to investigate the potential of seaweed as a safe and acceptable option for 85 
dietary iodine supplementation, specifically answering the following research questions: 86 
1) What is the bioavailability of iodine from an encapsulated edible seaweed 87 
(Seagreens® Ascophyllum nodosum species), in a group of asymptomatic non-88 
pregnant women reporting to consume low amounts of iodine-rich foods? 89 
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2) What is the impact of daily consumption of the encapsulated seaweed on iodine levels 90 
and thyroid function, in the same group of women?  91 
3) Is the encapsulated seaweed acceptable for consumers (taste / use)? 92 
 93 
Material and Methods 94 
Seaweed supplement 95 
Each capsule contained 0.5g Seagreens Ascophyllum nodosum (Napiers Hebridean Seagreens 96 
Capsules - NaHS), equivalent to 356 µg iodine (suppliers information based on 97 
measurements from independent UKAS accredited laboratories). NaHS is a dried and milled 98 
seaweed, sourced in Scotland and produced to distinct human food seaweedTM standards 99 
(patents pending) ensuring the safety, quality, sustainability and consistency of the products. 100 
All products are rigorously monitored during harvesting, drying and milling, and analyzed 101 
independently by UKAS accredited laboratories for nutritional composition, contaminants 102 
and heavy metals. 103 
In vitro iodine bioavailability assays 104 
The in vitro determination of the bioavailability of iodine in seaweed is based on the simple 105 
simulation of gastric and intestinal digestion according to the method developed by Romaris 106 
Hortas et al. 18. 107 
Digestion was carried out in triplicate. In brief, powdered NaHS (0.5 g) was added to distilled 108 
water (20mL) and the pH was adjusted to 2.0 with a 6M hydrochloric acid. Fresh gastric 109 
solution (0.15 g, pepsin 6.0% (w/v) dissolved in 6.0M HCl) was added to the flask, prior to 110 
incubation (37°C in a shaking bath at 150 rpm for 120 minutes). Digestate aliquots (0.5 mL) 111 
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were transferred to -20°C prior to iodine determination. The digestate pH was neutralized 112 
with NaOH (pH 7.5). Dialysis bags filled with 0.15N PIPES (20 mL) were placed inside each 113 
flask, along with intestinal digestion solution (pancreatin 4.0% (m/v) and bile salts 2.5% 114 
(m/v) dissolved in 0.1M sodium hydrogen carbonate, 5mL). The flasks were incubated at 115 
37°C in a shaking water bath at 150 rpm for 120 min. The enzymatic reaction was stopped by 116 
immersing the flasks in an ice water bath. The dialysis bags were removed and residual or 117 
non-dialyzable fraction (remaining slurries in the flasks) were transferred to polyethylene 118 
vials and separately weighed. Aliquots (1.5 mL) from the dialysate (20 mL) and non-119 
dialysate fractions (25 mL) were transferred to - 20°C prior iodine determination.  120 
Colonic fermentation of the digestate was carried out as previously described 19 to test 121 
whether iodine was trapped in the seaweed matrix after digestion. Briefly, faecal samples 122 
(16g) from three healthy volunteers were homogenized with a blender (30 s) in fermentation 123 
buffer (50 mL) to make a 32% faecal slurry. An aliquot (5 mL) of the non-dialyzable fraction 124 
of the intestinal digestate was added to faecal slurries (50 mL). The bottle was purged with 125 
OFN (1 min) and sealed and incubated in a shaking water bath at 37°C and 60 stroke/min. 126 
Samples were taken at t= 0h, 2h, 4h, 6h and 24h to measure pH and were immediately stored 127 
at -20°C prior to iodine determination. 128 
Human iodine bioavailability experimental design 129 
The study was approved by the University of Glasgow Medical Veterinary and Life Sciences 130 
College Ethics committee. All participants provided written informed consent.  131 
Healthy women aged 18-46, self-reporting as low-iodine consumers, were recruited locally 132 
using via posters and word-of-mouth, to take part in cross-over iodine bioavailability study. 133 
Those with existing thyroid or gastro-intestinal conditions, taking medication other than the 134 
contraceptive pill or smoking were excluded, as well as pregnant or lactating women and 135 
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those planning to conceive. Those taking dietary supplements containing iodine were also 136 
excluded. Appropriate sample size for bioequivalence / bioavailability studies vary between 137 
12 and 24 subjects. According to Hauschke et al., 20 participants are required for standard 2 x 138 
2 cross-over studies, with a bioequivalence range of 0.8-1.25, using a conservative 20% 139 
coefficient of variation (with ±=0.05, ² =0.80) 20. 140 
Height, weight, waist circumference and blood pressure were measured after recruitment.  141 
Usual dietary intake was determined using an iodine-specific food frequency questionnaire 21. 142 
Participants were allocated at random to treatment order (potassium iodine (KI) or seaweed 143 
first) and were asked to avoid all iodine-rich foods (dairy and seafood) for the duration of the 144 
study. Prospective food diaries were kept for the duration of the study. The iodine content of 145 
participants diet was determined by entering all foods in a dietary assessment software 146 
(Windiets 2005, Robert Gordon University) using appropriate food composition tables 22. A 147 
7-day wash out period between each leg of the cross-over intervention. Participants were 148 
asked to replicate their diet during the second leg of the study. 149 
All urine passed on Day 1 (baseline 24h urines) was collected. On Day 2, participants 150 
received either a seaweed supplement (NaHS, 1 g) or potassium iodide (KI) supplement 151 
(equivalent iodine content; 712 µg) to be taken fasted with a breakfast of white toast and a 152 
glass of water. Urine was collected for 24 hours, in fractions for the periods 0-2h, 2-5h, 5-8h, 153 
8-20h and 20-24h. 154 
Seaweed supplementation study – experimental design 155 
Healthy women aged 18-50, self-reporting as low-iodine consumers, were recruited locally 156 
using via posters and word-of-mouth, to take part in cross-over seaweed supplementation 157 
study. Those with existing thyroid or gastro-intestinal conditions, or taking medication other 158 
than the contraceptive pill were excluded, as well as those taking iodised dietary 159 
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supplements. None had taken part in the bioavailability study. The supplementation study 160 
was approved by the University of Glasgow Medical Veterinary and Life Sciences College 161 
Ethics committee. All participants provided written informed consent. The a priori sample 162 
size was calculated in G Power (Kiel University, Germany) using UIC as a primary outcome 163 
for mean difference between two groups using the Wilcoxon signed-Rank test for matched 164 
pairs, assuming a logistic parent distribution. A sample size of n=42 was calculated, to detect 165 
(or not) an increase from the current population UIC for the target group (median 75ug/L, 166 
calculated mean 94 µg/L, standard deviation 80 µg/L 10) to a sufficient UIC (100 µg/mL), 167 
equivalent to a ~14% increase in UIC, and an effect size of 0.47, with ±=0.05, ² =0.80). 168 
Participants’ height, weight, waist circumference and blood pressure were measured at the 169 
beginning and end of the supplementation period. Usual dietary intake was determined using 170 
an iodine-specific food frequency questionnaire 21. During the run-in period, participants 171 
were asked to keep a 4-day weighed food diary. Urine was collected for 24 hours on Day 4. 172 
On day 5, participants were supplied with a stock of supplements, and instructed to consume 173 
one capsule of NaHS daily (0.5 g per day, equivalent to an intake of 356 µg/d of iodine) for 174 
14 days, while following their usual diet. A fasted venous blood sample was collected, and 175 
the total volume of the urine collection measured. At the end of the supplementation period, 176 
participants replicated the diet recorded on the 4-day weighed diary (Days 16-19), and 177 
collected 24-hour urine on the last day of supplementation (Day 19). A final fasted venous 178 
blood sample was collected (Day 20). All urine and plasma samples were aliquoted and 179 
stored at -80˚C until analysis. Compliance was checked by counting the number of capsules 180 
remaining in the container supplied to volunteers. 181 
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Urinary iodine measurements 182 
Urinary iodine and iodine concentration in digestates were analysed using the colorimetric 183 
Sandell-Kolthoff reaction adapted for the 96-well microtiter plate, as described by Ohashi et 184 
al. 23, using a custom-made sealing cassette. Sample were measured in triplicates (CV% 185 
<10%).  186 
Thyroid function tests 187 
Thyroid stimulating hormone (TSH), thyroglobulin (Tg), triiodothyronine (T3 and fT3) and 188 
thyroxine (T4 and fT4) were measured in plasma in duplicates using immunoassays (ELISA 189 
assays, Astra biotech GmBh, Luckenwalde, Germany). 190 
Acceptability of the supplement 191 
Participants filled a self-administered questionnaire focusing on habitual frequency of 192 
consumption of seaweed products (6-point Likert scale, “daily” to “never”), opinions on taste 193 
(3 statements, 5-point Likert scales, “strongly agree” to “strongly disagree”), after-taste (1 194 
statement, 5-point Likert scales, “strongly agree” to “strongly disagree”) and overall 195 
acceptability of seaweed as a food or ingredient (3 statements, 5-point Likert scales, “strongly 196 
agree” to “strongly disagree”). Open questions were used to gather information on taste, after 197 
taste, and views on seaweed as an ingredient in foods. 198 
Statistical analyses 199 
Data were expressed as mean ± SD or as median and inter-quartile range (IQR) depending on 200 
normality, which was checked using the Shapiro-Wilks test. Categorical data (Likert scale) 201 
was described using the mode and IQR. Significance was implied at p<0.05. Wilcoxon 202 
signed-Rank test for matched pairs or paired t-test was used to assess the difference between 203 
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paired groups depending on their data distribution, while the Mann-Witney U-test or 204 
independent t-test was used to compare unrelated samples. Analysis was carried out using 205 
SPSS 18.0 (SPSS Inc., Chicago, IL, USA).   206 
 207 
Results 208 
In vivo bioavailability study 209 
Healthy females (n=22), median age 24.5 (IQR 22-34) were recruited and completed the 210 
bioavailability study. Socio-demographic and anthropometric details for the group are 211 
summarized in Table 1. 212 
Dietary iodine intake was low (below 55 µg/day) throughout the bioavailability study period, 213 
for each study arm (Table 2). The baseline median UIC, for the 24 hours preceding the study, 214 
was 40 µg/L (IQR 24-66) prior to seaweed intake and 31 µg/L (IQR 19-71) prior to KI 215 
intake. Correcting for total urine volumes, this was equivalent to 50 µg/24h (IQR 40-82) 216 
preceding seaweed intake, and 48 µg/24h (IQR 32-86) preceding KI intake. 217 
Urinary iodine output, in µg.L-1.h-1 is presented in Figure 1, with cumulated iodine excretion 218 
in µg presented in Figure 2. The peak iodine excretion time occurred earlier for KI (0-2h) 219 
compared to the seaweed (2-5h). The amount of iodine excreted over the 24h period 220 
following ingestion was greater (p<0.001) following KI intake (421 µg, IQR 328-526) 221 
compared to seaweed intake (239 µg, IQR 199-352). 222 
Participants were grouped according to habitual iodine intake, as either sufficient (n=7) or 223 
insufficient (n=13). The dose of iodine excreted in urine was calculated based on the iodine 224 
load of the NaHS capsule / KI plus the dietary iodine intake of day 3 (Table 2). The dose of 225 
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iodine excreted was significantly higher (p<0.001) following KI intake (59%, IQR 46-74) 226 
than seaweed intake (33%, IQR 28-46). This was true for both subgroups (p=0.009 and 227 
p=0.017 for insufficient and sufficient group, respectively). However, while the dose of 228 
iodine excreted after KI was higher in the sufficient group (73% vs. 46%, p=0.036), there was 229 
no difference between groups after seaweed ingestion (46% vs 31%) (Table 3).  230 
In vitro bioavailability assays 231 
After digestion in the simulated gastric compartment, only 9.9±0.1% of the iodine present in 232 
the sample was available and in solution. After digestion in the simulated intestinal 233 
compartment, 4.9±0.1% of the initial iodine dose present was recovered in the dialysis bag, 234 
with a further 5.0±0.0% in the non-dialysable fraction. This indicates that approximately 90% 235 
of the iodine was still trapped in the seaweed matrix at that point and consistent with the 236 
cumulated dose excretion in urine during the in vivo bioavailability study (up to 5h post 237 
ingestion), which was approximately 12% of the dose ingested (IQR 7-15). After faecal 238 
fermentation of an aliquot of the non-dialysable fraction, 51.2±10.4% of the iodine present 239 
was available, and in solution. 240 
Impact of seaweed supplementation on urinary iodine 241 
A total of 42 healthy females of childbearing age took part in the 2-week supplementation 242 
study. The demographic, anthropometric and dietary profiles of participants are presented in 243 
Table 4.  244 
At baseline, median UIC was well below the cut-off for sufficiency (100 µg/L) at 78 µg/L 245 
(IQR 39-114). The group average iodine intake was 110 µg (IQR 73-141), with 31 246 
participants with an intake below the recommended intake of 140 µg/day. Subsequently, 247 
individuals were classified as having iodine-sufficient (>140 µg) or insufficient intake (<140 248 
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µg) based on their habitual iodine consumption as estimated by the FFQ. There was no 249 
difference in weight, BMI, waist circumference between the subgroups with sufficient or 250 
insufficient iodine intake at baseline.  251 
After supplementation, median UIC increased significantly to 140 µg/L (IQR 103-194) 252 
(p<0.001). This increase in UIC differed between sufficient and insufficient group (+23 µg/L, 253 
IQR 17-66 for the sufficient group, +97 µg/L, IQR 57-132 for the insufficient group; 254 
p=0.041) and was only statistically significant in participants with insufficient habitual iodine 255 
intake (p<0.001). The total amount of iodine excreted over 24 hours was however 256 
significantly increased for both insufficient, from 93 µg/day (IQR 60-109) to 262 µg/day 257 
(IQR 198-301), p<0.001, and sufficient groups, from 138 µg/day (IQR 73-157) to 214 µg/day  258 
(IQR 75-343 µg/day), p<0.041. Neither weights nor waist circumferences changed during the 259 
supplementation study. 260 
Impact of seaweed supplementation on thyroid function 261 
The thyroid function tests are presented in Table 5. At baseline, Tg and fT3 levels were 262 
different between iodine sufficient and insufficient subgroups (p=0.047 and p=0.048, 263 
respectively). Tg values were within the Tg reference range in healthy adults (3 - 40 µg/L) 264 
but higher than the proposed cut-off for iodine sufficiency (10 µg/L).  265 
TSH levels were within the normal range (0.4 – 4.5 mUI/L) 24 for all but one participant, who 266 
had a borderline TSH level of 5.72 (but normal fT4 levels).  267 
There was no significant change in the thyroid hormones T3, T4, fT3, fT4 following 268 
supplementation, or Tg (with values remaining over 10 µg/L) 25. There was however a 269 
significant increase in TSH, from a median 1.5 mUI/L (IQR 1.2-2.2) to 2.1 mUI/L (IQR 1.3-270 
2.9) (p<0.001). This increase was significant in both insufficient and sufficient groups 271 
(p=0.027 and p=0.006, respectively), but more marked in those with sufficient habitual iodine 272 
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intake (p=0.044).  Serum TSH did exceed the normal range for two participants (7.3 and 8.0 273 
mUI/L) with fT4 still within the normal range. While fT3 levels did not significantly change 274 
for the whole group, those in the insufficient group had a decrease after supplementation 275 
(p=0.048). 276 
Seaweed consumption and acceptability of the supplement 277 
Participants in the bioavailability and supplementation studies answered a side questionnaire 278 
on seaweed consumption (combined n=63). They had very rarely been exposed to seaweed as 279 
a foodstuff, with 19% never having consumed it knowingly; 60% of participants had 280 
consumed it as sushi, on a monthly basis (18%) or less often (37%). Less than half (40%) of 281 
participants had consumed whole seaweed (less than twice a year). Most had never consumed 282 
lava bread (90%), nor seaweed as a tablet (92%) or a capsule (87%). The main reasons for the 283 
low consumption was lack of opportunity (mentioned by 64% of participants), and lack of 284 
appeal (54%). 285 
Participants agreed that the taste of the supplement was acceptable when swallowed as a 286 
capsule (mode 5, median 4, IQR 3-5) and disagreed that there was an unpleasant after-taste 287 
(mode 2, median 2, IQR 2-4) or that the capsule were difficult to swallow (mode 1, median 2, 288 
IQR 1-2). Supplementation study participants who had added the seaweed to foods (n=24) 289 
neither agreed nor disagreed on the acceptability of its taste as an ingredient (mode 3, median 290 
3, IQR 3-3) or its ease of use for cooking (mode 3, median 3, IQR 3-4).  291 
Participants agreed that encapsulated seaweed is a good way to include seaweed in the diet 292 
(mode 4, median 4, IQR 4-5). Preferred ways to consume seaweed included encapsulated 293 
(71%), as an ingredient in food (33%) or as a whole food (19%). Most (67%) saw the 294 
potential use of seaweed as a food ingredient as a positive. The main reasons where assumed 295 
health benefits and extra nutrients (35%) and flavour enhancement (24%). A minority (7%) 296 
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held negative view on seaweed as an ingredient, with taste the main concern (75%). The rest 297 
were either unsure or with no opinion.  298 
 299 
Discussion 300 
This study showed that asymptomatic young women with diets low in seafoods and dairy 301 
products do indeed display biochemical evidence of quite marked iodine deficiency.  It then 302 
shows how an acceptable/palatable commercially available seaweed product can boost the 303 
iodine intake of a group of mostly iodine-insufficient women, without deleterious impact on 304 
thyroid function. Even in an iodine-sufficient population (UIC above 100 µg/L), the 305 
consumption of this product (or product of similar quality and traceability) would not be 306 
contraindicated because the urinary iodine levels attained would not exceed 500 µg/L.  307 
Daily intake of an encapsulated seaweed (NaHS) was effective at raising the UIC of a group 308 
of females after a two-week supplementation period with a slight increase in the TSH levels 309 
after seaweed supplementation. Our results are in agreement with Teas et al. who 310 
supplemented iodine-replete healthy post-menopausal women with Alaria esculenta capsules 311 
for 7 weeks (475 µg iodine/day) 26 and Clark et al. (kelp, 1 g iodine/day for 6 weeks) 27. The 312 
TSH levels remained within the normal range for all but two participants, with no change 313 
observed for the thyroid hormones, whereas Clark et al observed a decrease in total T3 after 314 
supplementation. Tg values remained higher than the proposed 10 µg/L cut-off for iodine 315 
insufficiency 25, even after the supplementation, which might be indicative of a lag period for 316 
Tg values to fall within iodine sufficiency range after achieving iodine sufficient status.  317 
The iodine contained in NaHS was bioavailable, although to a lesser extent (30%) than 318 
previously reported by Aquaron (90-100% for iodine-sufficient women, and 62-85% for 319 
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iodine-insufficient women over 48-hours) 28 or Teas (60% for iodine-sufficient women over 320 
48-hours) 26. This may be directly related to our shorter (24-hour) urine collection, and the 321 
type of seaweed used in the other studies (Gracillaria verrucosa, Laminaria hyperborea and 322 
Alaria esculenta).  Incomplete collections are also a possible explanation. We showed a 323 
difference in excretion between those with either sufficient or insufficient iodine intake, as 324 
previously described 28. This is consistent with the generally-held understanding that most of 325 
the iodine will be excreted in urine if iodine stores are replete. In vitro digestion confirmed 326 
limited release of the iodine from the seaweed matrix in the first gastric and intestinal phases 327 
of simulated digestion.  We showed that colonic fermentation of seaweed is important to free 328 
iodine from the seaweed matrix, with mechanism relying on fermentation of the 329 
polysaccharide matrix 29 or metabolism of organic iodine 18. Therefore, the seaweed matrix 330 
may delay iodine absorption (compared to KI), with iodine released from the food over a 331 
longer period. Impact of further processing such as cooking needs to be taken in 332 
consideration if seaweed is used as an ingredient, as it would lead to partial loss via 333 
evaporation 30; 17.  334 
Several studies reported that iodine insufficient populations were diagnosed with iodine-335 
induced hyper- or hypothyroidism following high iodine intake 31; 32; 33; 34, however, a two-336 
week iodine supplementation with up to 500 µg/d had no impact on thyroid function tests in 337 
euthyroid subjects 35. Upper tolerable limit of iodine intake in healthy individuals have been 338 
defined as 1.1 mg/d in the United States and 600 µg/d in the European Union 36; 37. While 339 
epidemiological evidence has linked high daily seaweed/iodine intake with higher thyroid 340 
cancer risk in Japan 38, this observation is not supported by experimental studies in rats with 341 
chronic high iodine intake (up to 1g/L in drinking water) 39. The thyroid gland can adapt to 342 
excessive iodine intake after initial diminution in the excretion of thyroid hormone due to the 343 
Wolff-Chaikoff effect. This effect was demonstrated to have a longer lasting suppression of 344 
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the thyroid gland in those ingesting excess seaweed 40. Restricting the seaweed intake was 345 
able to reverse iodine-induced goiter and transient hypothyroidism 41.  346 
Reports of widespread iodine insufficiency in Britain and other Europeans countries, the 347 
renewed interest in iodine nutrition and the lack of iodine prophylaxis in the UK represent an 348 
opportunity for seaweed as a foodstuff.  Iodine insufficiency results from low intake of dairy 349 
(especially milk, which consumption has been steadily decreasing since 1975 42), and seafood 350 
(which consumption is low in the UK population at 37g/day 43). Iodised salt is the main 351 
method of iodine prophylaxis worldwide but there is still a concern, among clinical and 352 
public health professionals, that attributing a positive, health promoting characteristic to salt 353 
may blunt the public health effort toward salt reduction in relation to the prevention of 354 
cardiovascular diseases. A recent join WHO/ICCIDD meeting debated this topic, to synergise 355 
salt reduction and iodine fortification agendas 44. With table salt usage falling in the UK 356 
following successful public health campaigns, it may be contradictory to portray salt as a 357 
vehicle for iodine. Viable alternatives to increase iodine status include fortification of staple 358 
foods with seaweed, which was previously successfully incorporated in a nutritionally-359 
balanced pizza, designed in the context of health-by-stealth improvement of ready meals. 360 
Seaweed addition enabled to reduce the sodium content of the product, while improving 361 
nutritional content, without compromising the taste or appearance45. Given that iodine is 362 
extensively stored in the thyroid, it can safely be consumed intermittently, which makes 363 
seaweed use in a range of foods attractive, and occasional seaweed intake enough to ensure 364 
iodine sufficiency. 365 
Seaweed consumption in most Western cultures has been low, due to low availability in the 366 
market and poor consumer awareness regarding potential health benefits 46. The benefits of 367 
incorporating seaweed isolates into the habitual diet goes further than addressing iodine 368 
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deficiency, with impact of seaweed consumption on serum oestradiol, reduction of the 369 
glycemic response to a carbohydrate load, and increased satiety via lowered gastric emptying. 370 
These aspects may be relevant to the development of functional foods for weight 371 
management 47; 48; 49; 50; 51. Incorporation in bread had no impact on taste or appearance 46. 372 
Trade price are such that the additional cost per loaf would be minimal considering that 373 
seaweed is iodine-rich and that little would be required.  374 
The contaminants and heavy metal content of seaweed is sometimes a concern, especially in 375 
retailed products with poor traceability and limited compositional analysis, as consumption 376 
may expose the consumer to heavy metals such as organic / inorganic arsenic 52. Water 377 
quality is important for seaweed quality, and France is the only European country with 378 
specific regulations for the use of seaweeds as vegetables 30. The seaweed used in this study 379 
(NaHS) was grown in Scottish Grade A Pristine water (SEPA/SNH evaluation) and produced 380 
to Human Food SeaweedTM  standards (patents pending). Compositional analysis, carried out 381 
on every batch, showed no contaminants and heavy metals below threshold levels. This is 382 
important if seaweed will become a more commonly used ingredient in processed foods.  383 
In conclusion the answers to the research questions behind this study are: 384 
1) Iodine bioavailability from the encapsulated seaweed was low in the group of women 385 
studied. The seaweed matrix may be a key factor for this low bioavailability.  386 
2) Daily consumption of 0.5g of NaHS increased urinary iodine level to 140 µg/L for the 387 
group. TSH increased slightly, within the normal range for all but two participants. 388 
Increase in TSH level may be linked to iodine-induced hypothyroidism, especially in 389 
those with replete iodine stores, although no change to thyroid hormones levels were 390 
observed 40.  391 
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3) Participants indicated that the encapsulated seaweed had an acceptable taste, was easy 392 
to use, and were positive about seaweed use as an ingredient. 393 
 394 
The study conclusions would have been strengthened with a randomised controlled crossover 395 
study design, longer exposure time and reassessment of iodine status and thyroid function 396 
after the end of the intervention, but that would demand an impractical duration of high 397 
tolerance from volunteers.  It would be of value to repeat the biochemical aspects in different 398 
subject groups.  The influence of the seaweed matrix on bioavailability will be an important 399 
factor to consider if seaweed is incorporated in cooked and uncooked staple foods. A large-400 
scale survey needs to take place to properly investigate attitudes to seaweed utilisation in 401 
processed foods and cuisine in general. 402 
  403 
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Figure legends 528 
 529 
Figure 1: Urinary iodine excretion in µg/L/h over 24h, after ingestion of a dose of 712µg 530 
iodine, from KI () or NaHS (). 531 
Figure 2: Cumulated iodine output in µg over 24h, after ingestion of a dose of 712µg iodine, 532 
from KI () or NaHS (). 533 
  534 
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Table 1: Characteristics of the bioavailability study participants (n=22) 535 
    Median IQR 
Demographic & anthropometric details Age (yrs) 24.5 22-34 
Height (cm) 165 163-167 
Weight (kg) 60 56-70 
Waist (cm) 71 66-77 
BMI (kg/m2) 22 20-24 
Usual diet Milk (mg/day) 131 92-236 
 Other dairy (mg/day) 115 81-172 
 Seafood inc. fish (mg/day) 24 13-29 
 Daily iodine intake (µg/day) 127 87-142 
    Count (n) (%) 
Ethnicity White British 6 27% 
 White Europeans 4 18% 
 Other ethnicities 12 55% 
Body composition Overweight (BMI>25) 3 14% 
  Obese (BMI>30) 1 5% 
Iodine intake Daily iodine intake >140 µg/day 7 33% 
  Daily iodine intake <140 µg/day 14 67% 
 536 
 537 
 538 
 Table 2: Daily dietary iodine intake (µg) according to study arm  539 
 Study arm Day 1 Day 2 Day 3 
 
median IQR median IQR median IQR 
NaHS - KI 54 32-84 45 29-65 39 28-64 
KI - NaHS 53 33-58 48 26-91 38 25-65 
 540 
 541 
Table 3: Percentage iodine dose excreted, according to habitual iodine intake (sufficient & insufficient) 542 
  Seaweed KI 
 
median IQR median IQR 
insufficient (n=13) 31%  a 6-14 46%  b 40-72 
sufficient (n=7) 46%  a 33-49 73% b 64-77 
All (n=22) 33% a 28-46 59% b 46-74 
a,b significantly different change (”  pre-post supplementation) between groups at p<0.05 543 
 544 
 545 
 546 
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 547 
 548 
 549 
Table 4: Characteristics of the participants in the 2-week supplementation study (n=42) 550 
    Median IQR 
Anthropometric and 
demographic 
information 
 
Age (yrs) 27.0 22-37 
Height (cm) 164 162-168 
Weight (kg) 62 57-71 
Waist (cm) 72 67-82 
BMI (kg/m2) 23 21-26 
Usual diet Milk (mg/day) 180 79-259 
 Other dairy (mg/day) 71 37-159 
 Seafood inc. fish (mg/day) 20 8-38 
 Daily iodine intake (µg/day) 110 70-139 
    Count (n) (%) 
Ethnicity White British 25 60% 
 White Europeans 9 21% 
 Other ethnicities 8 19% 
Body composition Overweight (BMI>25) 10 24% 
  Obese (BMI>30) 4 10% 
Iodine intake Daily iodine intake >140 µg/day 11 26% 
  Daily iodine intake <140 µg/day 31 74% 
 551 
 552 
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Table 5: Iodine status and thyroid function pre and post supplementation in participants meeting the daily iodine recommendation (n=11) or not (n=31). Data are 
presented as median (IQR). 
 
  All (n=42) Insufficient (n=31) Sufficient (n=11) 
  Pre Post Δ Pre Post Δ Pre Post Δ 
UIC  
(μg/L) 78 (39-114) 
 
140 (103-194) *** 72 (23-129) 
 
50 (38-99) 
 
149 (105-194) *** 97 (57-132) a 104 (85-122) 
 
139 (106-200) 
 
23 (17-66) b 
UIC  
(μg/24h) 94 (61-142) 
 
248 (177-305) *** 147 (82-190) 
 
93 (60-109) 
 
262 (198-301) *** 149 (102-195) 
 
138 (73-157) 
 
214 (75-343) * 76 (25-167) 
 TSH  
(mUI/L) 1.5 (1-2) 
 
2.1 (1-3) *** 0.5 (0-1) 
 
1.4 (1.1-2.2) 
 
1.9 (1.2-2.8) * 0.4 (-0.1-0.8) a 1.7 (1.4-2.2) 
 
2.7 (2.2-3.2) ** 0.8 (0.6-1.3) b 
Tg  
(µg/L) 21.8 (16.8-32.1) 
 
20.6 (17-30.1) 
 
-1.0 (-3.6-2.5) 
 
26.6 (17.2-35) 
 
24.0 (17.6-31.8) 
 
-1.7 (-3.8-3.1) 
 
17.2 (12-22.9) 
 
15.8 (14.7-20.2) 
 
-0.4 (-1.7-1.8) 
 T3  
(nmol/L) 1.9 (1.7-2.2) 
 
1.9 (1.7-2.2) 
 
-0.1 (-0.2-0.1) 
 
1.9 (1.7-2.3) 
 
2.0 (1.7-2.1) 
 
-0.1 (-0.3-0.1) 
 
1.9 (1.8-2) 
 
1.9 (1.7-2.3) 
 
-0.1 (-0.2-0.1) 
 T4  
(nmol/L)  86.9 (75.6-97.4) 
 
86.0 (75.9-102.1) 
 
2.3 (-3.2-11.7) 
 
89.9 (77.9-101.1) 
 
86.9 (75-110.8) 
 
-0.3 (-4.6-8.1) 
 
80.8 (72.9-85) 
 
83.8 (79.3-98.3) * 2.9 (1.3-14.9) 
 
fT3 (pmol/L) 5.5 (3.3-7.7) 
 
4.4 (2.9-6.7) 
 
-0.2 (-1.2-0.4) 
 
4.1 (3.1-7) 
 
3.3 * (2.9-6.6) 
 
-0.3 (-1.3-0.1) 
 
6.8 (5.8-8.2) 
 
6.8 (5.6-8.1) 
 
0.0 (-0.5-1) 
 
fT4 (pmol/L) 13.8 (12.4-15.6)   14.4 (12.4-15.9)   0.4 (-0.6-1.1)   13.9 (12.1-15.6)   14.5 (12.3-15.6)   0.4 (-0.5-0.9)   13.5 (12.9-15.4)   14.3 (12.8-16.5)   0.2 (-1.0-1.7)   
”  difference between parameters measured pre and post supplementation 
* p<0.05, ** <p<0.01, *** p<0.001 pre vs post supplementation 
a,b significantly different change (”  pre-post supplementation) between groups at p<0.05 
